» Articles » PMID: 20359463

Involvement of Natural Killer T Cells in Halothane-induced Liver Injury in Mice

Overview
Date 2010 Apr 3
PMID 20359463
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Drug-induced liver injury (DILI) causes significant patient morbidity and mortality, and is the most common reason for drug withdrawals. It is imperative to gain a thorough understanding of the underlying mechanisms of DILI to effectively predict and prevent these reactions. We have recently developed a murine model of halothane-induced liver injury (HILI). The aim of the present study was to investigate the role of hepatic natural killer T (NKT) cells in the pathogenesis of HILI. The degrees of HILI were compared between WT and CD1d(-/-) mice, which are deficient in NKT cells. The data revealed that CD1d(-/-) mice were resistant in developing HILI. This resistance appeared to be a direct result of NKT cell depletion rather than an indirect one due to the absence of cross-talk between NKT cells and other hepatic innate immune cells. Compared with WT mice, CD1d(-/-) mice exhibited a significantly lower number of hepatic infiltrating neutrophils upon halothane challenge (470,000+/-100,000/liver in WT vs. 120,000+/-31,500/liver in CD1d(-/-) mice). This result in conjunction with our previous finding of an indispensable role of neutrophils in HILI strongly suggests that NKT cells play a critical role in regulating neutrophil recruitment, thereby contributing to the development of HILI. Collectively, the current study and published reports indicate that this murine model of HILI provides an experimental system for the investigation of the underlying mechanisms of DILI. In addition, this model may yield the discovery of susceptibility factors that may control the development of liver injury in patients treated with halothane and potentially other drugs.

Citing Articles

Nanotherapeutics for Alleviating Anesthesia-Associated Complications.

Lu B, Wei L, Shi G, Du J Adv Sci (Weinh). 2024; 11(15):e2308241.

PMID: 38342603 PMC: 11022745. DOI: 10.1002/advs.202308241.


Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury.

Tasnim F, Huang X, Lee C, Ginhoux F, Yu H Front Toxicol. 2022; 3:605392.

PMID: 35295156 PMC: 8915912. DOI: 10.3389/ftox.2021.605392.


Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models.

Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D Int J Mol Sci. 2021; 22(9).

PMID: 33925355 PMC: 8123708. DOI: 10.3390/ijms22094557.


The Impact of Invariant NKT Cells in Sterile Inflammation: The Possible Contribution of the Alarmin/Cytokine IL-33.

Ferhat M, Robin A, Barbier L, Thierry A, Gombert J, Barbarin A Front Immunol. 2018; 9:2308.

PMID: 30374349 PMC: 6197076. DOI: 10.3389/fimmu.2018.02308.


Activation of natural killer T cells contributes to triptolide-induced liver injury in mice.

Wang X, Xue R, Zhang S, Zheng Y, Zhang L, Jiang Z Acta Pharmacol Sin. 2018; 39(12):1847-1854.

PMID: 30013034 PMC: 6289391. DOI: 10.1038/s41401-018-0084-9.


References
1.
Stanic A, Dharshan de Silva A, Park J, Sriram V, Ichikawa S, Hirabyashi Y . Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci U S A. 2003; 100(4):1849-54. PMC: 149922. DOI: 10.1073/pnas.0430327100. View

2.
Tacke F, Luedde T, Trautwein C . Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol. 2008; 36(1):4-12. DOI: 10.1007/s12016-008-8091-0. View

3.
Coquet J, Chakravarti S, Kyparissoudis K, McNab F, Pitt L, McKenzie B . Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A. 2008; 105(32):11287-92. PMC: 2516267. DOI: 10.1073/pnas.0801631105. View

4.
Laan M, Cui Z, Hoshino H, Lotvall J, Sjostrand M, Gruenert D . Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol. 1999; 162(4):2347-52. View

5.
Temple R, Himmel M . Safety of newly approved drugs: implications for prescribing. JAMA. 2002; 287(17):2273-5. DOI: 10.1001/jama.287.17.2273. View